The following undesirable effects have been observed and reported during treatment with Argipressin with the following frequency:
The undesirable effects are listed below by organ class and the following frequency convention:
Very common: (≥1/10)
Common: (≥1/100, <1/10)
Uncommon: (≥1/1,000, <1/100)
Rare: ((≥1/10,000, <1/1,000)
Very rare: (<1/10,000),
Not known – frequency cannot be estimated from the available data.
The frequency of the following side effects is not known.
Immune system disorders
• hypersensitivity
• anaphylaxis
Metabolism and nutrition disorders
• hyperhydration / water intoxication
Nervous system disorders
• headache
• vertigo
• tremor
Cardiac disorders
• chest pain due to angina
• cardiac arrest
Vascular disorders
• peripheral ischaemia
• pallor
• hypertension
Respiratory, thoracic and mediastinal disorders
• bronchospasm
Gastrointestinal disorders
• flatulence
• nausea
• vomiting
• diarrhoea
• abdominal pain
Skin and subcutaneous tissue disorders
• gangrene
• hyperhidrosis
• urticaria
Renal and urinary disorders
• fluid retention
General disorders and administration site conditions
• non-cardiac chest pain
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the yellow card scheme at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.